Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Long-term results

Prada, Pedro J.; Anchuelo, J.; Blanco, Ana; Payá, Gema; Cardenal, Juan; Acuña, E; Ferri, María; Vázquez, Andrés; Pacheco, Maite; Sánchez, Juan Escámez

doi:10.1590/s1677-5538.ibju.2014.0531

Cited by 7 publications

(5 citation statements)

References 21 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the study by Prada et al [17] published in 2016, we can also draw results that are like those of our series, even though it is a smaller sample of patients, 57 patients were studied, all with previous TUR, from which results were obtained for Survival free of biochemical recurrence, Overall Survival and Survival free of local recurrence. The sample included patients with low and intermediate risk and 40% received hormone therapy for 3 months.…”

Section: Survival Free Of Biochemical Recurrencesupporting

confidence: 83%

Relationship between D90 and D100 with Biochemical and Local Failure in Low-risk Prostate Cancer Treated with Low-rate Brachytherapy (LDR)

Morcillo

Villoslada

Castellón

et al. 2022

Jour. of oncol. res.

View full text Add to dashboard Cite

Low dose rate brachytherapy (LDR) is an accepted, effective treatment with few local side effects, used as monotherapy in patients with low-risk prostate cancer (PC). The aim of this paper is to analyse 245 patients treated with LDR in the Radiation Oncology Department of the Hospital Gómez Ulla, from 2004 to 2016, evaluating the relationship of dosimetric parameters with biochemical and local recurrence as well as genitourinary and gastrointestinal toxicity derived from the technique. The results obtained show a clear relationship between the dose used and biochemical and local failure.

show abstract

Section: Survival Free Of Biochemical Recurrencesupporting

confidence: 83%

Relationship between D90 and D100 with Biochemical and Local Failure in Low-risk Prostate Cancer Treated with Low-rate Brachytherapy (LDR)

Morcillo

Villoslada

Castellón

et al. 2022

Jour. of oncol. res.

View full text Add to dashboard Cite

show abstract

“…In the study by Prada et al . [ 6 ], 57 patients with clinically localized prostate cancer that underwent LDR brachytherapy were followed up for a period of 10 years. Follow-up 5-year data revealed biochemical control, tumor-free survival, and OS were 94%, 96%, and 88%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Several institutions have reported 5- and 10-year biochemical relapse-free survival ranging from 94-96% [ 2 , 3 , 4 ] to 87-98.5% [ 3 , 5 , 6 , 7 ], respectively. In addition, a number of reviews have demonstrated that LDR brachytherapy is equally effective as EBRT or radical prostatectomy (RP) alone in patients with newly diagnosed low- or intermediate-risk prostate cancer [ 8 , 9 , 10 ]; however, Rodrigues et al .…”

Section: Purposementioning

confidence: 99%

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes

Chao

Spencer

Guerrieri

et al. 2018

jcb

View full text Add to dashboard Cite

PurposeTo report the 5-year biochemical relapse-free survival (BRFS), overall survival (OS), and long-term toxicity outcomes of patients treated with low-dose-rate (LDR) brachytherapy as monotherapy for low- to intermediate-risk prostate cancer.Material and methodsBetween 2004 and 2011, 371 patients were treated with LDR brachytherapy as monotherapy. Of these, 102 patients (27%) underwent transurethral resection of the prostate (TURP) prior to implantation. Follow-up was performed every 3 months for 12 months, then every 6 months over 4 years and included prostate specific antigen evaluation. The biochemical relapse-free survival (BRFS) was defined according to the Phoenix criteria. Acute and late toxicities were documented using the Common Terminology Criteria for Adverse Events version 4.0. The BRFS and OS estimates were calculated using Kaplan-Meier plots. Univariate and multivariate analyses were performed to evaluate outcomes by pre-treatment clinical prognostic factors and radiation dosimetry.ResultsThe median follow-up of all patients was 5.45 years. The 5-year BRFS and OS rates were 95% and 96%, respectively. The BRFS rates for patients with Gleason score (GS) > 7 and GS ≤ 6 were 96% and 91% respectively (p = 0.06). On univariate analysis, T1 and T2 staging, risk-group classification, and prostate volumes had no impact on survival at 5 years (p > 0.1). Late grade 2 and 3 genitourinary (GU) toxicities were observed in 10% and 5% of patients respectively. Additionally, patients with prior TURP had a greater incidence of late grade 2 or 3 urinary retention (p = 0.001). There were 14 deaths in total; however, none were attributed to prostate cancer.ConclusionsLDR brachytherapy is an effective treatment option in low- to intermediate-risk prostate cancer patients. We observed low biochemical relapse rates and minimal GU toxicities several years after treatment in patients with or without TURP. However, a small risk of urinary retention was observed in some patients.

show abstract

“…However, subsequently, Wallner et al reported only a 6% incontinence rate at 3 years in 19 patients treated with prostate seed implant after previous TURP, and there have been a number of retrospective reports of post-TURP brachytherapy with low urinary toxicity rates [6,8,9,24,25,26]. These are shown in Table 2.…”

Section: Discussionmentioning

confidence: 99%

A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial

Salembier¹,

Henry²,

Pieters³

et al. 2020

jcb

View full text Add to dashboard Cite

Purpose: Early reports suggested that transurethral resection (TURP) prior to permanent seed brachytherapy (BT) results in high incontinence rates. Guidelines consider prior TURP as a contra-indication to treatment, but improvements in imaging and treatment planning may reduce this risk, and are investigated in this prospective study. Material and methods: 99 men with histologically proven low-to intermediate-risk, localized prostate cancer, with a history of TURP performed at least 3 months before BT procedure were enrolled. All patients received a permanent seed implant between March 2009 and June 2015. Intra-operative interactive planning was recommended to ensure optimal accuracy of seed placement during the procedure. No supplemental external beam was allowed. Target and organ at risk contouring, definition of clinical target volume (CTV), and dosimetric parameters followed the modified GEC-ESTRO guidelines for permanent seed implants, as described an earlier report of our group. Follow-up was scheduled every 3 months for the first year, and every 6 months afterwards, with minimum follow-up of 2 years. Study endpoints: The primary endpoint was the incidence of post-implant urinary incontinence. Secondary endpoints were the incidence of urinary and gastro-intestinal toxicity, the eventual impact on the sexual function, and the freedom from biochemical failure. Results: The median follow-up time for these 99 patients was 49 months (min. 24, max. 96). In this series, the incontinence rate was 2% after TURP + BT and 2% in case of TURP + BT + re-TURP, ending up with a total urinary incontinence rate of 4%. Acute and late urinary toxicities were extremely low. No significant late gastro-intestinal toxicity was seen, and the 5-year biochemical non-evidence of disease (bNED) was 93%. Conclusions: The excellent long-term results and low morbidity presented as well as many advantages of prostate brachytherapy over other treatments demonstrates that brachytherapy is an effective treatment for patients with transurethral resection and organ-confined prostate cancer.

show abstract

Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Long-term results

Cited by 7 publications

References 21 publications

Relationship between D90 and D100 with Biochemical and Local Failure in Low-risk Prostate Cancer Treated with Low-rate Brachytherapy (LDR)

Relationship between D90 and D100 with Biochemical and Local Failure in Low-risk Prostate Cancer Treated with Low-rate Brachytherapy (LDR)

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes

A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial

Contact Info

Product

Resources

About